Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
ILC 2021: Symposium „Old and new treatments for patients with advanced cirrhosis”
Very successful symposium on Thursday, 24th June 2021 from 14-15h CEST organised by members of MICROB-PREDICT in the frame of the virtual ILC congress. Topics included:
- Why and how to modulate the microbiome: example from MICROB-PREDICT study (Shawcross)
- Old drugs for novel treatment strategies (Posé)
- Human albumin: from established indications to novel perspectives (Caraceni)
- System medicine: is it the right track to personalized treatments: example from DECISION study? (Trebicka)
MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021
Successful MICROB-PREDICT and DECISION – Online Symposium ‘Management of acute-on-chronic liver failure’ on Thursday, 2nd September 2021 from 12.30 - 16.30h CEST which was organised at the occasion of the EASL School of Hepatology.
With almost 100 registered attendees and speakers from 37 countries our symposium was a great success and we would like to thank everyone for their participation and the lively discussions.